267 related articles for article (PubMed ID: 31411982)
1. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
2. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
Mollica V; Rizzo A; Massari F
Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
[No Abstract] [Full Text] [Related]
3. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
[No Abstract] [Full Text] [Related]
4. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
5. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Takahashi T
Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251
[No Abstract] [Full Text] [Related]
6. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
Li J; Chen B; Cao D
Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
[No Abstract] [Full Text] [Related]
7. Cytoreductive nephrectomy in the era of targeted therapies: a review.
Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
[TBL] [Abstract][Full Text] [Related]
8. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
9. Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.
Ishiyama Y; Urabe F
Eur Urol Oncol; 2024 Jun; 7(3):642-643. PubMed ID: 38238222
[No Abstract] [Full Text] [Related]
10. Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.
Marconi L; Lam TB; Bex A; Ljungberg B; Volpe A
Eur Urol; 2016 Jun; 69(6):e119-20. PubMed ID: 26776936
[No Abstract] [Full Text] [Related]
11. A commentary on 'The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis' [Int J Surg (2023) 109:982-994].
Wang Q; Shi H; Sun Y; Feng W; Xu H; Wang H
Int J Surg; 2024 Apr; 110(4):2458-2459. PubMed ID: 38668669
[No Abstract] [Full Text] [Related]
12. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
13. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
Eur Urol Oncol; 2024 Apr; 7(2):302-303. PubMed ID: 38000932
[No Abstract] [Full Text] [Related]
14. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
[TBL] [Abstract][Full Text] [Related]
15. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis.
García-Perdomo HA; Zapata-Copete JA; Castillo-Cobaleda DF
Investig Clin Urol; 2018 Jan; 59(1):2-9. PubMed ID: 29333508
[TBL] [Abstract][Full Text] [Related]
16. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
Ghoreifi A; Djaladat H
Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
[No Abstract] [Full Text] [Related]
17. Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
Massari F; Di Nunno V; Santoni M
Eur Urol Oncol; 2019 May; 2(3):340-341. PubMed ID: 31200852
[No Abstract] [Full Text] [Related]
18. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Graham J; Bhindi B; Heng DYC
Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
[TBL] [Abstract][Full Text] [Related]
20. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]